Managed Care
Disease
Management

Specialty drugs increasingly used to treat chronic conditions

MANAGED CARE August 2007. © MediMedia USA
Managed Care Outlook

Specialty drugs increasingly used to treat chronic conditions

MANAGED CARE August 2007. ©MediMedia USA













In the beginning, about three or four years ago, specialty drugs were primarily used to treat rare genetic conditions such as Gaucher's disease or diseases such as multiple sclerosis. However, they are being used increasingly to control chronic illnesses, which accounts in part for the increased demand.

Although less than 3 percent of people are using specialty medications, these patients account for 25 percent to 30 percent of an insurer's overall costs. Express Scripts reports that claims for specialty drugs increased 18.8 percent between 2003 and 2004, compared with 9.4 percent for traditional drugs. The company expects spending on specialty drugs to double over the next four years, accounting for more than 25 percent of outpatient pharmacy spending by 2008. Duane Barnes, vice president of Aetna Pharmacy Management Fulfillment Operations and Aetna Specialty Pharmacy, says that "in 2005, specialty drugs accounted for about $55 billion in ... drug expenditures, but are expected to climb to $1.7 trillion by 2030."

Projected spending on specialty drugs, 2004 vs. 2008

Late-stage biotech drugs in development

Note: Percentages do not add up to 100% because some biotechnology drugs fall into more than one category.

Source: Curascript Pharmacy, 2004 Specialty Pharmacy Management Guide & Trend Report, June 2005.

Note: Totals are not 100 because percentages are rounded.

Source: Wyeth Trend Report Series 2007. Specialty Pharmacy Management Insights.

Meetings

HealthIMPACT Southeast Tampa, FL January 23, 2015

Our other journal

P&T Journal for November 2014

Features

LETTER TO THE EDITOR

Medications for Parkinson’s Disease

PERSPECTIVE

The Changing Roles of P&T Committees

Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies

PIPELINE PLUS

Modest Growth Seen in Epilepsy Market

MEETING HIGHLIGHTS

European Society of Cardiology and Transcatheter Cardiovascular Therapeutics

BOOK REVIEW

“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD

DEPARTMENTS

MEDICATION ERRORS

Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment

PRESCRIPTION: WASHINGTON

FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds

New Drugs/Drug News

Pharmaceutical Approval Update

DRUG FORECAST

Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension